CHEST:病毒学抑制的HIV感染者发生肺炎是否结局更糟糕?

2017-03-18 MedSci MedSci原创

近期,一项发表在杂志CHEST上的研究旨在调查在病毒学上抑制HIV感染者(CD4 + T细胞计数> 350细胞/ mm 3)发生肺炎球菌肺炎的临床表现和结果(住院时间(LOS),重症监护病房(ICU)入院率和30天死亡率是否与非HIV感染的患者中观察到的相当。此项研究使用病例对照设计,研究在Hospital Clinic,Barcelona,Spain(2001-2016)进行。对照组在同一

近期,一项发表在杂志CHEST上的研究旨在调查在病毒学上抑制HIV感染者(CD4 + T细胞计数> 350细胞/ mm 3)发生肺炎球菌肺炎的临床表现和结果(住院时间(LOS),重症监护病房(ICU)入院率和30天死亡率是否与非HIV感染的患者中观察到的相当。


此项研究使用病例对照设计,研究在Hospital Clinic,Barcelona,Spain(2001-2016)进行。对照组在同一日历期间的年龄(±10岁)、性别、共病和肺炎诊断与试验组相匹配。研究比较了HIV感染患者和非HIV感染患者的肺炎球菌肺炎的临床表现和结果。

此项研究结果显示:在50例(HIV感染)和100例对照(非HIV感染)者中研究肺炎球菌肺炎。与对照组患者相比,病例患者的流感率(14%vs. 2%,p = 0.007)和肺炎球菌接种率(10%对1%,p = 0,016)更高。病例组的HBV共感染率也较高(6%vs. 0%,p = 0,036)。两组患者ICU入院率分别为18%vs 27%(P = 0.22),使用机械通气(12%vs. 8%,P = 0.43),住院时间,(7天vs.7天,p <0.76)和30天死亡率(0%),上述指标组间无显著差异。没有发现在病例中比对照组更严重的临床表现或更差的临床结果。

此项研究得出结论:在病毒学抑制的HIV感染患者中(≥350个CD4 + T细胞计数/ mm3)需要住院的肺炎球菌性肺炎,与未感染HIV的患者相比既不严重,也没有更差的预后。这些研究结果支持这样的事实,即这群患者不需要与一般群体不同的治疗、入院或护理。

原始出处:
Cillóniz C, Torres A, Manzardo C, et al. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. Chest. 2017 Mar 13. pii: S0012-3692(17)30368-9. doi: 10.1016/j.chest.2017.03.007. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929299, encodeId=903b1929299ed, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Oct 18 23:52:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050613, encodeId=34392050613f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 24 09:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290215, encodeId=8f2a129021517, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603330, encodeId=5e5316033306e, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180919, encodeId=3105180919c3, content=文章不错,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Mar 18 15:58:46 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2017-10-18 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929299, encodeId=903b1929299ed, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Oct 18 23:52:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050613, encodeId=34392050613f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 24 09:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290215, encodeId=8f2a129021517, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603330, encodeId=5e5316033306e, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180919, encodeId=3105180919c3, content=文章不错,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Mar 18 15:58:46 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929299, encodeId=903b1929299ed, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Oct 18 23:52:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050613, encodeId=34392050613f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 24 09:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290215, encodeId=8f2a129021517, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603330, encodeId=5e5316033306e, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180919, encodeId=3105180919c3, content=文章不错,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Mar 18 15:58:46 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929299, encodeId=903b1929299ed, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Oct 18 23:52:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050613, encodeId=34392050613f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 24 09:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290215, encodeId=8f2a129021517, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603330, encodeId=5e5316033306e, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180919, encodeId=3105180919c3, content=文章不错,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Mar 18 15:58:46 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2017-03-20 周虎
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929299, encodeId=903b1929299ed, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Oct 18 23:52:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050613, encodeId=34392050613f5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 24 09:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290215, encodeId=8f2a129021517, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603330, encodeId=5e5316033306e, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Mon Mar 20 05:52:00 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180919, encodeId=3105180919c3, content=文章不错,值得分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Mar 18 15:58:46 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2017-03-18 1e10c84am36(暂无匿称)

    文章不错,值得分享

    0

相关资讯

Nature:广谱的抗HIV中和抗体疗法优于抗HIV反转录的鸡尾酒疗法

广谱的抗HIV的中和抗体疗法不同于传统的抗反转录的鸡尾酒疗法,能够引起长期的CD8 T细胞的免疫机制从而抑制HIV病毒量。

Nature:新治疗可持久控制 HIV 病毒

现在,来自洛克菲勒大学和国家卫生研究院的新研究表明,在感染后立即用两种抗 HIV 抗体治疗使免疫系统有效地控制病毒。

Nature:一个蛋白揪出HIV潜伏者

长期以来,科学家们在HIV感染疗法和预防性策略研究领域中投入了大量的精力去探索研究,但是不幸的是,目前并没有彻底攻克HIV,虽然高效的抗逆转录病毒疗法已经帮助了数以百万计的HIV患者。但是试图治愈艾滋病毒一直被一种特定类型的免疫细胞阻碍,它们可以隐藏病毒,为其提供避难所。使得这些被感染的T细胞可以逃避体内免疫系统的检测,很难被识别杀死。只要治疗一停止,就会马上进行传播,几十年之后也还是如此,后患无

Nature:艾滋研究新突破,抗体带来持久保护

艾滋病在世界范围内广泛传播,严重威胁着人类健康和社会发展,一直受到人们的高度重视。近十年来 HIV 的治疗和预防已经取得了巨大的进步,HIV 携带者的寿命大大延长,新 HIV 感染者增长速度也有所降低。但人们仍未找到治愈这种疾病的有效途径,也没有开发出相应的疫苗。2016 年《自然·医学》(Nature Medicine)公布了一项新成果:美国俄勒冈国家灵长类动物研究中心的科学家们通过研究展示,在

Nature:重磅!发现CD4 T细胞HIV病毒库的标志物---CD32a

在一项新的研究中,法国研究人员发现一种方法能够在服用抗HIV药物的人体内精确地找到给人类免疫缺陷病毒(HIV)提供藏身之所的仍未得到充分理解的白细胞。相关研究结果于2017年3月15日在线发表在Nature期刊上,论文标题为“CD32a is a marker of a CD4 T-cell HIV reservoir harbouring

Eur Heart J:HIV阳性患者他汀一级预防是否安全有效?

发表在《Eur Heart J》的一项由意大利和美国科学家进行的系统评价和荟萃分析,考察了人类免疫缺陷病毒阳性患者他汀一级预防的相对安全性和有效性。